161 related articles for article (PubMed ID: 26702763)
1. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
3. Health care costs among renal cancer patients using pazopanib and sunitinib.
Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
[TBL] [Abstract][Full Text] [Related]
4. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Xu CF; Johnson T; Garcia-Donas J; Choueiri TK; Sternberg CN; Davis ID; Bing N; Deen KC; Xue Z; McCann L; Esteban E; Whittaker JC; Spraggs CF; Rodríguez-Antona C; Pandite LN; Motzer RJ
Br J Cancer; 2015 Mar; 112(7):1190-8. PubMed ID: 25695485
[TBL] [Abstract][Full Text] [Related]
5. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
[TBL] [Abstract][Full Text] [Related]
6. The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Artaç M
Eur J Clin Pharmacol; 2024 Jun; 80(6):941-947. PubMed ID: 38478093
[TBL] [Abstract][Full Text] [Related]
7. Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.
Gilabert M; Provansal M; Cappiello M; Walz Y; Salem N; Tarpin C; Brunelle S; Thomassin J; Gravis G
Br J Cancer; 2013 Oct; 109(7):1750-4. PubMed ID: 24045668
[TBL] [Abstract][Full Text] [Related]
8. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L
Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib-induced enteritis in a patient with renal cell carcinoma.
Ariyoshi M; Hayashi R; Takasago T; Yamashita K; Hiyama Y; Yuge R; Urabe Y; Ueno Y; Shimamoto F; Oka S
Clin J Gastroenterol; 2024 Jun; 17(3):434-440. PubMed ID: 38407743
[TBL] [Abstract][Full Text] [Related]
10. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.
Pinkhas D; Ho T; Smith S
Cardiooncology; 2017; 3():. PubMed ID: 29497565
[TBL] [Abstract][Full Text] [Related]
11. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Guerin E; Man S; Xu P; Kerbel RS
Cancer Res; 2013 May; 73(9):2743-8. PubMed ID: 23610448
[TBL] [Abstract][Full Text] [Related]
12. Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Cooper SL; Carter JJ; March J; Woolard J
Pharmacol Res Perspect; 2019 Jun; 7(3):e00477. PubMed ID: 31164986
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib in the treatment of advanced renal cell carcinoma.
Cella D; Beaumont JL
Ther Adv Urol; 2016 Feb; 8(1):61-9. PubMed ID: 26834841
[TBL] [Abstract][Full Text] [Related]
15. Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors.
Gupta S; Nichols P; Lohse CM; Kosari F; Kattah AG; Harris FR; Karagouga G; Mehra R; Fine SW; Reuter VE; Herrera-Hernandez L; Zganjar AJ; Britton CJ; Potretzke AM; Boorjian SA; Thompson RH; Jimenez RE; Leibovich BC; Garovic VD; Cheville JC; Sharma V
Mayo Clin Proc; 2022 Nov; 97(11):2050-2064. PubMed ID: 35753824
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis.
Sur D; Coroama CI; Audisio A; Fazio R; Coroama M; Lungulescu CV
J Pers Med; 2024 May; 14(5):. PubMed ID: 38793102
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection.
Tsujinaka K; Izawa-Ishizawa Y; Miyata K; Yoshioka T; Oomine K; Nishi H; Kondo M; Itokazu S; Miyata T; Niimura T; Sato M; Aizawa F; Yagi K; Chuma M; Zamami Y; Goda M; Ishizawa K
Biomed Pharmacother; 2023 Nov; 167():115504. PubMed ID: 37722188
[TBL] [Abstract][Full Text] [Related]
18. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
[TBL] [Abstract][Full Text] [Related]
19. Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.
Diaz J; Sternberg CN; Mehmud F; Delea TE; Latimer N; Pandite L; Motzer RJ
Oncology; 2016; 90(3):119-26. PubMed ID: 26901053
[TBL] [Abstract][Full Text] [Related]
20. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
